Scotia Capital Inc. Arbutus Biopharma Corp Transaction History
Scotia Capital Inc.
- $17.8 Billion
- Q3 2024
A detailed history of Scotia Capital Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Scotia Capital Inc. holds 14,740 shares of ABUS stock, worth $53,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,740
Previous 18,740
21.34%
Holding current value
$53,506
Previous $57,000
1.75%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.5MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$78.8 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$46.7 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$41.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$32.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$30.4 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $544M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...